Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BRP0
UPID:
OVOL2_HUMAN
Alternative names:
Zinc finger protein 339
Alternative UPACC:
Q9BRP0; Q5T8B4; Q9BX22; Q9HA54; Q9Y4M0
Background:
Transcription factor Ovo-like 2, also known as Zinc finger protein 339, plays a pivotal role in maintaining epithelial lineages, suppressing epithelial-to-mesenchymal transition, and positively regulating neuronal differentiation. It is crucial for the development of primordial germ cells and plays dual functions in thermogenesis and adipogenesis to maintain energy balance.
Therapeutic significance:
Linked to Corneal dystrophy, posterior polymorphous, 1, through mutations affecting its gene, understanding the role of Transcription factor Ovo-like 2 could open doors to potential therapeutic strategies.